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Edited by Robert BaroukiAbstract Visfatin has been originally identiﬁed as a growth fac-
tor for early stage B cells and recently known as an adipokine.
Here, we report that hypoxia induces the visfatin mRNA and
protein levels in MCF7 breast cancer cells. We also demonstrate
that induction of visfatin gene is regulated by hypoxia-inducible
factor-1a (HIF-1a). Moreover, 5 0-ﬂanking promoter region of
human visfatin gene contains two functional HIF responsive ele-
ments (HREs), activating the expression of visfatin. Mutation of
these HREs in the visfatin promoter abrogates activation of a
luciferase reporter gene driven by visfatin promoter under hypox-
ia. Taken together, our results demonstrate that visfatin is a new
hypoxia-inducible gene of which expression is stimulated through
the interaction of HIF-1 with HRE sites in its promoter region.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Adipokines are biologically active polypeptides growth fac-
tors and cytokines that appear to be preferentially produced
by adipose tissue [1,2]. They exert their eﬀects on the normal
and neoplastic breast tissues by endocrine and paracrine mech-
anisms; in most cases, they are also secreted by cancerous epi-
thelial cells, providing for autocrine regulation [3]. They can
stimulate cancer epithelial cell proliferation, invasion, and
angiogenesis which is essential for breast cancer development
and progression [3].
Visfatin (pre-B-cell colony-enhancing factor) is ﬁrstly iso-
lated from peripheral blood lymphocyte and recently charac-
terized as a novel adipokine [4,5]. In addition, visfatin is*Corresponding author. Fax. +82 51 245 8388.
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[5–9]. More recently, acute mechanical and multiple inﬂamma-
tory stimuli increased visfatin expression [6,7], but precise
mechanism(s) underlying this visfatin induction remains
poorly resolved. Furthermore, molecular mechanism of visfa-
tin gene regulation in tumor progression has not been eluci-
dated yet.
Hypoxia detected in the central regions of solid tumors can
be a leading cause of angiogenesis, a fundamental determinant
of malignant tumor progression [10,11]. A key factor in this
process is hypoxia-inducible factor (HIF), which regulates
transcription of hypoxia-activated genes and consists of HIF-
1a and HIF-1b heterodimer. The a subunit of HIF-1 is rapidly
degraded under normoxic condition and stabilized under hy-
poxia, while HIF-1b is expressed constitutively [12]. Since the
production of many adipokines including leptin, IL-6, VEGF,
and heparin-binding epidermal growth factor-like growth fac-
tor are tightly regulated by hypoxia [13–17], we hypothesized
that hypoxic microenvironment within tumor mass activates
the expression of visfatin.
In this present study, we investigated whether the expression
of visfatin is upregulated in response to hypoxia and further
examined whether the HIF-1 is involved in hypoxia-induced
activation of human visfatin gene in breast cancer MCF7 cell
line. Herein, our data provide evidence that hypoxic induction
of visfatin gene is mediated by transactivation of HIF-1
through HIF-1 consensus binding site (HRE) in the proximal
promoter of visfatin gene.2. Materials and methods
2.1. Reagents and antibodies
Cobalt chloride and L-mimosine were from Sigma. Mouse monoclo-
nal anti-HIF-1a and a-tubulin antibodies were purchased from BD
transduction laboratories and Biogenex, respectively. Rabbit and
mouse monoclonal anti-visfatin antibodies were from AdipoGen.
Alexa 594-conjugated goat anti-mouse IgG was purchased from
Molecular Probes.
2.2. Cell culture
MCF7 cells, Hepa-1c4 and Hepa-1c1c7 cells were maintained in
DMEM supplemented with 10% FBS (Invitrogen) and 1% antibiotics.
For hypoxic condition, cells were incubated at 5% CO2 level with 1%
O2 balanced with N2 in hypoxic chamber (Forma Scientiﬁc).blished by Elsevier B.V. All rights reserved.
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A genomic DNA fragment of the human visfatin gene [6] containing
2 kb of 5 0-ﬂanking region was prepared by PCR ampliﬁcation of hu-
man genomic DNA. A 1949 bp PCR product was obtained and sub-
cloned into a pCR2.1/TA vector (Invitrogen). From this construct, a
full-length (p(1949)luc) and a deletion mutant of visfatin gene
(p(708)luc) were ampliﬁed by PCR and subcloned into pGL3 luciferase
reporter vector (Promega), respectively. All constructs were conﬁrmed
by automatic DNA sequencing analysis.
2.4. Real-time PCR
Real-time PCR quantiﬁcation was performed using a SYBR Green
approach (Light Cycler; Roche Applied Science, Penzberg, Germany).
Cycling parameters consisted of 1 cycle of 95 C for 10 min, followed
by ampliﬁcation for 30 cycles of 95 C for 10 s, 57 C for 5 s, and
72 C for 7 s. Subsequently, a melting curve program was applied with
continuous ﬂuorescence measurement. The entire cycling process
including data analysis took less than 1 h and was monitored using
the LightCycler software program (version 4.0).
2.5. Immunocytochemistry
Cells cultured on a coverglass were ﬁxed in 4% paraformaldehyde
for 10 min, blocked with 0.5% Triton X-100/PBS for 5 min, and then
labeled with appropriate primary antibodies and Alexa 594-conjugated
secondary antibody. Coverslips were mounted in Vectastain containing
DAPI (Vector Laboratories). Cells were analyzed using ﬂuorescent
microscopy (Nikon).
2.6. RNA interference experiment
MCF7 cells were transfected with siRNA speciﬁc for HIF-1a (anti-
sense: 5 0-UCAAACACACUGUGUCCAG-3 0; sense: 5 0-CUGGA-
CACGUGUGUUUGA-30) at a concentration of 100 nM using the
Lipofectamine 2000 (Invitrogen). After transfection, the cells were ex-
posed to a normoxic or hypoxic atmosphere for the indicated times.
2.7. Transient transfection and reporter gene analysis
Cells were plated on 24-well plates and transfected with the lucifer-
ase constructs and pCMV-b-gal using Lipofectamine 2000 (Invitro-
gen). On the following day, the cells were incubated with hypoxic
condition for 20 h and then solubilized. Cell lysates were analyzed
for b-galactosidase enzyme assay and for luciferase activity using assay
kit (Promega) and luminometer (Turner Designs). Each extract was as-
sayed at least three times, and relative luciferase activity was calculated
as RLU/b-galactosidase.
2.8. Site-directed mutagenesis
Six putative HIF-1 binding sites (HRE: 5 0-RCGTG-3 0) within
p(708)luc were targeted for mutagenesis. The mutations were made
with a QuickChange site-directed mutagenesis kit (Stratagene) and
checked by automatic DNA sequencing.
2.9. Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) analysis was performed
with the ChIP kit (Upstate Biotechnology) according to the manufac-
turer’s instructions with minor modiﬁcations and anti-HIF-1a mono-
clonal antibody (Novus). Chromatins were immunoprecipitated from
1 · 106 cells incubated under normoxia and hypoxia for 16 h, respec-
tively. Sequences of promoter-speciﬁc primers included the visfatin
promoter region 383 to 258 as follows: sense, 5 0-AGAGCT-
GGCGTCTGGGAG-30; and anti-sense, 5 0-GCCTTCACCCCGT-
CACCC-3 0.
2.10. Immunohistochemistry
Human breast cancer tissue specimens were prepared and thin sec-
tions (4 lm) from selected areas were used. In brief, after deparaﬃni-
zation and blocking of endogenous peroxidase activity, antigen
retrieval was routinely performed using PBS containing 0.04% alkaline
protease solution (Promega). The primary monoclonal antibodies used
in this study were mouse anti-pan-visfatin and rabbit anti-HIF-1a. Tis-
sues were stained according to the standard avidin–biotin method
using ABC reagent (Vectastain Elite kit, Vector Labs.) and counter-
stained with Harris hematoxylin.3. Results
3.1. Hypoxia increases human visfatin mRNA and protein levels
To examine the eﬀects of hypoxia on visfatin gene expres-
sion, MCF7 cells were incubated under hypoxic condition
for periods of 16 h and 24 h. As shown in Fig. 1A, hypoxic
treatment produced signiﬁcant increases in visfatin mRNA lev-
els. Using real-time RT-PCR, we also quantiﬁed the enhanced
expression level of visfatin mRNA under hypoxia (Fig. 1B).
Next, to analyze whether hypoxic condition could aﬀect visfa-
tin protein levels, Western immunoblot analysis was per-
formed. As shown in Fig. 1C, 1% O2 and cobalt chloride,
hypoxic mimic agent, increased visfatin protein levels in a
time-dependent manner. The increased level of visfatin protein
by hypoxia was conﬁrmed by immunocytochemistry. As
shown in Fig. 1D, a stronger staining of visfatin protein was
observed in hypoxic MCF7 cells than in normoxic cells. These
results indicated that hypoxia signiﬁcantly upregulates visfatin
mRNA and protein levels.
3.2. Hypoxic induction of visfatin mRNA and protein is
dependent on HIF-1
HIF-1 is a key transcription factor of the transcriptional re-
sponses to hypoxia. To determine the crucial role of HIF-1a in
hypoxia-mediated upregulation of visfatine gene, we transfec-
ted HIF-1a expression vector into normoxic MCF7 cells. As
shown in Fig. 2A, the overexpressed HIF-1a increased the visf-
atin protein level even under normoxic condition, which shows
similar increase in the expression of visfatin under hypoxia.
The stability of HIF-1a protein is known to be markedly
downregulated by prolyl hydroxylase domain protein (PHD)
that hydroxylates HIF-1a under normoxia, followed by its
polyubiquitination and proteasomal degradation. We found
that treatment of normoxic MCF7 cells with L-mimosine, a
well-recognized PHD inhibitor [18], induced visfatin mRNA
levels (Fig. 2B). To conﬁrm whether endogenous visfatin gene
is one of direct HIF-1 target genes, we also used speciﬁc
siRNA against HIF-1a. Transfection of MCF7 cells with
siRNA against HIF-1a markedly reversed hypoxia-induced
visfatin expression (Fig. 2C). Thus, these data demonstrated
that HIF-1a is directly involved in the induction of the visfatin
gene expression.
3.3. Transcriptional activation of the visfatin gene promoter by
hypoxia
We next focused on detailed analysis of human visfatin pro-
moter to ﬁnd out functional HIF-1 binding sites. Therefore, we
searched putative HIF-1 binding sequences in 5 0-ﬂanking re-
gion of the human visfatin gene [6]. An extensive analysis of
5 0 visfatin promoter sequence (between positions 1949 and
+1), using the computer database TRANSFAC, revealed the
presence of several putative HIF-1 consensus-binding sites.
The relative position and orientation of these elements are
indicated at the top of Fig. 3. Based on this information, we
cloned two fragments containing up to 1949 bp and up to
708 bp of the 5 0-ﬂanking region of the human visfatin gene,
and then constructed luciferase reporter vectors, named as
p(1949)luc and p(708)luc, respectively. These constructs were
then introduced into MCF7 cells and incubated with hypoxia.
As shown in Fig. 3A, reporter activities of both constructs un-
der hypoxia were signiﬁcantly increased compared to that of
pGL3 alone. Because the transcriptional activity of p(708)luc
Fig. 1. Eﬀect of hypoxia on the expression of visfatin gene. (A) MCF7 cells were incubated under 21% O2 or 1% O2 for the indicated times. RT-PCR
analysis was performed using speciﬁc primers for human visfatin. b-actin served as an internal control. (B) MCF7 cells were incubated under
normoxic or hypoxic conditions for 16 h or 24 h. Total RNAs were isolated and then analyzed by real-time PCR using visfatin primers. The
expression level under normoxia (0 h hypoxia) was set to 100%, and the values are normalized to actin mRNA levels. (C) MCF7 cells were incubated
for the indicated times under 1% O2 or treated with 100 lM cobalt chloride. Visfatin protein levels were examined by Western blotting using anti-
visfatin. a-tubulin served as loading control. (D) Photographs showed immunocytochemically staining cells with anti-pan visfatin antibody. The
signals were detected using Alexa 594-conjugated secondary antibody (red).
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pected that potential functional HREs exist on fragment from
708 to +1, and then we used this fragment (from 708 to +1)
in the following experiments. To test whether exogenous HIF-
1a overexpression can cause the same stimulatory eﬀects on
visfatin promoter, HIF-1a expression vector was added with
p(708)luc. As expected, transfection of HIF-1a expression vec-
tor stimulated reporter activity even in normoxic condition:
this was further enhanced by the hypoxia (Fig. 3B). To deter-
mine whether the functional HIF-1 complex is required for
transcriptional activation of visfatin by hypoxia, we took
advantage of the mouse hepatoma Hepa-1c4 cells. This cell line
is derived from parental Hepa-1c1c7 cells and deﬁcient in HIF-
1b subunit, which fails to form functional HIF-1 heterodimer
[19]. The p(708)luc reporter construct was transiently transfec-ted into Hepa-1c4 cells and Hepa-1c1c7 cells under normoxic
or hypoxic conditions. The luciferase activities indicated a sub-
stantial induction in hypoxic Hepa-1c1c7 cells, whereas no sig-
niﬁcant increase was observed in Hepa-1c4 cells in response to
hypoxia (Fig. 3C). HIF-1a and HIF-2a are two highly related
pHLH/PAS homologous transcription factors that undergo in-
creased function at low oxygen levels [20]. Transcriptionally
active heterodimer composed of HIF-2a and ARNT, like
HIF-1a and ARNT, binds to HRE and activates hypoxia-in-
duced genes [21]. To check whether HIF-2a might be involved
in hypoxia-induced visfatin promoter activation, we performed
a luciferase assay using an p(708)luc reporter and HIF-2a. The
p(708)luc activity in the presence of HIF-1a was signiﬁcantly
increased, whereas no increase was observed in the presence
of HIF-2a expression vector (Fig. 3D). Thus, functional
Fig. 2. The role of HIF-1a in the regulation of visfatin gene expression. (A) MCF7 cells were transfected with HIF-1a expression vector and left
untreated or exposed to 1% O2 for 24 h. Anti-visfatin or HIF-1aWestern blotting from protein extracts was performed. a-tubulin served as a loading
control (left panel). The right panel showed densitometric analysis assessing relative visfatin protein expression level in at least three times
independent experiments. The density of the control bands (21% O2 for 24 h) was set to 100%. (B) Cell lysates were prepared fromMCF7 cells treated
with 400 or 800 lM L-mimosine for 16 h. RT-PCR analysis was performed using speciﬁc primers for visfatin or b-actin. (C) MCF7 cells were
transfected with siRNAs speciﬁc for HIF-1a or non-speciﬁc siRNA for negative control. After transfection, the cells were incubated under normoxic
(N) or hypoxic (H) conditions for 24 h and subjected to Western blot analysis against visfatin or HIF-1a (left). The relative visfatin protein expression
level was measured in at least three times independents followed by densitometry. The expression under normoxia transfected with control siRNA
was set to 100% (right).
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gene in response to hypoxia.
3.4. Identiﬁcation of functional HRE in human visfatin gene
promoter
To determine which elements within the region from 708 to
+1 of visfatin promoter are actually involved in hypoxia-
mediated visfatin gene induction, speciﬁc mutations were indi-
vidually introduced into the core sequence of the 8 putative
HRE motifs within p(708)luc construct. As shown in Fig. 4A,
although wild-type p(708)luc construct supported the hypoxic
induction of luciferase activity by 6-fold, this activation was de-
creased when the HRE-2, -4 or -5 motifs were mutated. More-
over, the enhanced luciferase activity under hypoxic condition
was abrogated markedly by 30% when the mutated HRE-4
(Mut4), or -5 (Mut5) constructs were transfected. Interestingly,
HRE sites of mutated HRE-4 and -5 motifs shared complete
conservation with the mouse and rat visfatin promoter (data
not shown). We further demonstrated that double mutationsof both HRE 4 and 5 located between 358 and 346 sites
completely abolished the hypoxic induction of p(708)luc con-
struct (Fig. 3B), indicating that these two HRE motifs are
essential and suﬃcient for the hypoxic visfatin response. Next,
to obtain direct evidence for the interaction between HIF-1a
and the visfatin promoter, we used ChIP assay to measure
the HIF-1a recruitment to the visfatin promoter. As shown in
Fig. 4C, HIF-1a bound eﬀectively to the visfatin promoter un-
der hypoxic treatment. In contrast, non-speciﬁc binding was
unaﬀected by hypoxia, as demonstrated by results using control
IgG as the primary antibody for immunoprecipitation.
3.5. Expression of visfatin and HIF-1a proteins in human breast
carcinoma
We next examined if there is a correlation between visfatin
and HIF-1a protein expression in human neoplastic breast tis-
sues. We carried out immunostaining of 22 human breast can-
cer tissues, applying anti-visfatin and anti-HIF-1a to sections
of human breast carcinoma. As shown in Fig. 5, visfatin (21
Fig. 3. Visfatin promoter sequences mediate transcriptional responses to hypoxia and HIF-1. (A) The location and orientation of putative HRE sites
within 5 0-ﬂanking region of the human visfatin gene deﬁned by the core sequence 5 0-RCGTG-3 0 were indicated at the top by the arrows. 1949-kb and
708-kb fragment of the 5 0-ﬂanking region of the human visfatin gene were subcloned into upstream of a luciferase reporter genes, respectively. MCF7
cells were transiently transfected with luciferase reporter vectors as indicated and subsequently incubated under hypoxia for 24 h. (B) MCF7 cells
were transfected with p(708)luc, pBOS-hHIF-1a, pBOS-hARNT, or pEF-BOS as indicated and then incubated under hypoxia for 20 h. (C) Hepa-
1c1c7 (wild-type) and the HIF-1b/ARNT-deﬁcient variant Hepa-1c4 cells were transfected with p(708)luc. Subsequently, the cells were incubated at
21% O2 (N: normoxia) or 1% O2 (H: hypoxia) for 20 h. (D) MCF7 cells were transfected with p(708)luc and HIF-1a or HIF-2a expression vector as
indicated and then incubated for 20 h. All data (A–D) expressed as percentage ± S.E. from at least three separate occasions with triplicate. RLA
means a relative luciferase activity.
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highly expressed in a malignant epithelium of nearly all of
the cases of human breast neoplasia. Interestingly, the expres-sion of HIF-1a was positively associated with visfatin, suggest-
ing the correlation between visfatin and HIF-1a in actual
breast tumors.
Fig. 4. Speciﬁcity of HIF-1 dependent activation and binding to the visfatin promoter sequences. (A) The regions of the mutated HRE-1–6 (Mut1–6)
are indicated by triangle at the top. The mutations in two base pairs in each of the HIF-1 binding sites are indicated in bold. MCF7 cells were
transfected with wild-type and mutated promotor constructs. After transfection, the cells were cultured at 1% oxygen for 20 h before the assessment
of luciferase activity. (B) MCF7 cells were transfected with wild-type and mutated HRE-4, -5, -4/5 (double mutation in both HRE-4 and -5 sites), and
then the cells were incubated at 1% O2 for additional 20 h. Each experiment was performed in triplicate on at least three separate occasions.
(C) MCF7 cells were cultured under normoxia (N) or hypoxia (H) conditions for 16 h as described and subjected to ChIP assay. Anti-HIF-1 a
polyclonal antibody (a-HIF-1a) or mouse IgG (a-IgG) was used to precipitate sonicated chromatin. Sonicated cell lysate (2 ll) was used as an input
control. The gel pictures are representative of three independent experiments. IP, immunoprecipitation.
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Visfatin is a secreted protein that is preferentially produced
in visceral adipose tissue and known as a novel adipokineexerting insulin-mimetic eﬀects on various insulin-sensitive tis-
sues [5]. The cDNA sequence of visfatin gene is identical to
that of pre-B cell colony-enhancing factor (PBEF) which was
originally cloned as a cytokine-like growth factor, expressed
Fig. 5. Immunostaining for visfatin and HIF-1a in human breast tumor. Sections of human breast cancer tissues were stained with antibodies that
recognize the visfatin and HIF-1a (bottom, 200·). Sections were stained without primary anti-visfatin and anti-HIF-1a antibodies as controls (top,
200·). Samples were counterstained with hematoxylin to reveal morphology.
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tor on early stage B cells [4]. In addition, visfatin has been re-
ported to be expressed not only in the various normal organ
tissues, but also in inﬂamed tissue under inﬂammatory stimuli
and tumor tissues such as doxorubicin-responsive breast can-
cer and colorectal cancer [4,6–9,22]. Although it was reported
using computer-based analysis of nucleotide sequences that the
proximal promoter region of the human visfatin contains a
number of putative binding motifs for transcription factors
[6], the molecular basis and detailed regulatory mechanism of
visfatin gene expression have not been elucidated yet.
In this report, we showed for the ﬁrst time that the human
visfatin gene is transcriptionally activated in response to hy-
poxia through a mechanism that involves binding of the
HIF-1 to functional HRE sites located within the proximal
promoter region. In support of this conclusion, we found that:
(i) low oxygen tension and CoCl2 increase visfatin mRNA and
protein levels in breast cancer cell line, (ii) exogenous overex-
pression of HIF-1a markedly induces visfatin expression,
whereas knockdown of HIF-1a using siRNA suppressed the
hypoxic induction of visfatin gene, (iii) the 5 0-ﬂanking region
of the human visfatin gene contains HREs that are necessary
and suﬃcient for hypoxia-induced transcriptional activation
of visfatin promoter-luciferase reporter gene, and (iv) the
immunopositive region for visfatin is positively associated with
HIF-1a in human breast tumor tissue.
Obesity is a risk factor for breast cancer in post-menopausal
women [23]. Circulating levels of adipokines are high in obesity
and stimulate the growth of breast cancer cells; some of these
are potentially involved in the regulation of angiogenesis which
process is important for progression of breast cancer [24]. For
example, leptin, one of typical adipokines, induces the prolifer-
ation of endothelial cells and elicits a marked enhancement ofangiogenesis [25]. In addition, the leptin is necessary to regu-
late adipose tissue expansion, which is one of the few sites of
active angiogenesis in adult [26,27]. Based on these reports,
we raised the possibility that visfatin may also regulate angio-
genesis. As expected, we found that visfatin protein accelerated
the formation of new blood vessel in chick chorioallantoic
membranes (unpublished data), suggesting that visfatin-medi-
ated angiogenesis may be involved not only in enlargement
of tumor mass but also in excessive growth of adipose tissue
for the settlement of obesity. We are now investigating about
molecular mechanism(s) for the angiogenic activities of visfatin
and elucidating the relationship between hypoxia and visfatin
gene induction in normal cell types including adipose cells
and normal breast cell lines. Recently, it is reported that visf-
atin promotes the eﬃcient acquisition of a stable and mature
smooth muscle cell phenotype that is essential for developing
and remodeling of blood vessel [28]. Therefore, visfatin may
act as a regulator for the maintenance of vascular homeostasis
in vascular endothelial and smooth muscle cells.
Our observations add the human visfatin gene to a list of
genes regulated by hypoxia via the HIF-1-dependent pathway.
Hypoxia, a common consequence of solid tumor growth in
breast cancer and other cancers, serves to propagate a cascade
of molecular pathways which include angiogenesis, glycolysis,
and alterations in microenvironmental pH [29]. Consistent
with a stimulatory eﬀect of a local hypoxic environment on
the expression of target genes in tumors, we showed marked
expression of visfatin gene in both hypoxia-treated breast can-
cer cells and human breast tumor tissues. Besides the role as a
tumor-promoting factor, hypoxia is one of key factors in path-
ogenesis of acute lung injury [30]. Recently, it was reported
that pre-B-cell colony-enhancing factor (also known as visfa-
tin) is a potential novel biomaker in acute lung injury [31].
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may participate in response to hypoxia in several pathological
situations.
We showed that HIF-1 and HIF-2 are not equally eﬀective
on the p(708)luc visfatin promoter, as HIF-1a protein was able
to induce the visfatin promoter at higher levels than HIF-2a
(Fig. 3D). The activation control reporter plasmid
pSV40pro-EpoHRE-Luc, containing the four HRE core se-
quence of erythropoietin gene, was also tested in reporter as-
say. However, either exogenous HIF-2a or HIF-1a induced
transcription of the control HRE reporter plasmid at similar
levels (data not shown), indicating the speciﬁcity of HIF-1
for the activation of visfatin promoter. In addition, several re-
ports showed that basal HIF-2a mRNA and protein level un-
der hypoxia were low or absent in the various breast cancer cell
lines, whereas these cells dramatically expressed the high-level
HIF-1a protein in response to hypoxia [32,33]. Recently, it has
been reported that the expression of hypoxia-induced genes
was critically dependent on HIF-1a but not HIF-2a in breast
cancer cells [34]. Based on these observations, we strongly sug-
gest that HIF-1a protein, rather than HIF-2a, may be predom-
inantly expressed in human breast cancer cells and
preferentially bind to HREs of the visfatin promoter, leading
to the activation of the human visfatin gene.
Hypoxia is not the only condition that stabilizes HIF-1a and
activates HIF-1 transcriptional activity. Several hormones,
growth factors and viral proteins, including insulin and insu-
lin-like growth factor [35,36], angiotensin II, thrombin and
platelet-derived growth factor [37], endothelin-1 [38], and Hep-
atitis B virus X protein [39], have been shown to increase the
level of HIF-1a in various cell types. In addition, inﬂammatory
cytokines, such as interleukin 1b and tumor necrosis factor a,
also induce HIF-1 activity in normoxic cells [40]. Considering
that multiple inﬂammatory stimuli (including lipopolysaccha-
ride, interleukins, and tumor necrosis factor a) signiﬁcantly in-
creased visfatin expression [6], it would be of interest to
investigate whether these stimuli could regulate visfatin gene
expression in some types of cells via hypoxia-independent
HIF-1 pathways. In Fig. 5, the expressional correlation be-
tween visfatin and HIF-1a genes was observed in neoplastic
human breast tissues, supporting our result that visfatin is
highly expressed under the regulation of HIF-1a protein.
However, since expressional ratio of visfatin (21 of 22 cases;
95.4%) was higher than that of HIF-1a (15 of 22 cases;
68.2%), we cannot exclude possibility that HIF-1-independent
pathway may be also involved in the regulation of visfatin gene
expression.
In conclusion, the data presented here are consistent with the
visfatin gene being a hypoxia-inducible gene. Moreover, we
demonstrated that hypoxia mediates the upregulation of visfa-
tin gene via HIF-1a and HIF-1-dependent transcriptional
activity, as described for several other genes regulated by low
oxygen availability. Our data may provide a molecular expla-
nation for patho-physiological regulation of visfatin in breast
tumorigenesis and a novel approach as a target for the devel-
opment of new therapeutic strategies.
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